| P2093 | author name string | Anders Bergh | |
| | Anders Widmark | |
| | Elin Thysell | |
| | Pernilla Wikström | |
| | Sead Crnalic | |
| | Emma Jernberg | |
| | Erik Bovinder Ylitalo | |
| | Stina Rudolfsson | |
| P2860 | cites work | Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate | Q42513600 |
| | Predicting survival for surgery of metastatic spinal cord compression in prostate cancer: a new score | Q43853936 |
| | Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer | Q46549099 |
| | Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease | Q46716649 |
| | Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases | Q48592065 |
| | Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases | Q57693579 |
| | Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease | Q71629976 |
| | Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding | Q71820064 |
| | Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients | Q84677595 |
| | Intraprostatic Steroidogenic Enzymes – Letter | Q85184048 |
| | Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival | Q21091046 |
| | Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor | Q24679336 |
| | A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth | Q28116222 |
| | Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer | Q30485336 |
| | Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant | Q30495758 |
| | Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer | Q33235187 |
| | Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer | Q34204078 |
| | Steroid hormone transforming aldo-keto reductases and cancer | Q34571239 |
| | Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. | Q34618859 |
| | Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer | Q34786897 |
| | Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance | Q35083279 |
| | Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone | Q35808422 |
| | Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal | Q36003940 |
| | Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. | Q36585622 |
| | Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth | Q36876865 |
| | Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors | Q36937170 |
| | Blockade of testicular and adrenal androgens in prostate cancer treatment | Q37829637 |
| | A new trick of an old molecule: androgen receptor splice variants taking the stage?! | Q37900501 |
| | Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically | Q37921011 |
| | Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. | Q39254330 |
| | The androgen axis in recurrent prostate cancer | Q39675435 |
| | Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer | Q39750288 |
| | Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol | Q39941487 |
| | Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer | Q39954334 |
| | The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor | Q40595377 |
| | Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer | Q41084688 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | e77407 | |
| P577 | publication date | 2013-11-07 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants | |
| P478 | volume | 8 | |